- Interim Final Rule Implements Controversial Surprise Billing Arbitration Provisions
(October 14, 2021)
- In Law360, Attorneys Analyze Takeaways from D.C. Circuit Medicare Advantage Overpayment Ruling (October 13, 2021)
-
In New York Magazine’s The Cut, Mark Barnes Discusses the Biden Administration’s COVID-19 Vaccine Mandate for Workers (October 1, 2021)
- Margaux Hall to Present at Managed Markets & Account Management Strategies Conference (November 9, 2021)
- Margaux Hall and Alison Fethke to Present at PLI Webcast on Drug Pricing Evolving Legal and Policy Landscape (September 20, 2021)
- In Barron’s and USA Today, Mark Barnes Examines Whether President Biden’s New Vaccine Mandate Can Withstand Legal Challenges (September 13, 2021)
- Proposed Rule on CY 2022 Physician Fee Schedule Addresses Telehealth (Especially Mental Health), Drug Pricing and Reimbursement, Provider Enrollment, Vaccines, and Physician-Owned Distributor Transparency (August 13, 2021)
- Updated: Developments in Drug Pricing and Price Reporting as the Congressional Recess Approaches (August 2021)
(August 11, 2021)
- Developments in Drug Pricing and Price Reporting as the Congressional Recess Approaches (August 2021)
(August 3, 2021)
- Podcast: Non-binding Guidance: COVID-19 Vaccine Mandate Litigation (July 29, 2021)
- In Law360, Health Care Attorneys Examine Compliance Considerations for Pharmaceutical Testing Programs (June 7, 2021)
- Margaux Hall and Alison Fethke to Present at PLI Webcast on Drug Pricing Evolving Legal and Policy Landscape (September 20, 2021)
- Mark Barnes Examines Subject-Sponsor Interactions in Report on Research Compliance (June 1, 2021)
- Health Care Attorneys Analyze the Future of Telehealth (May 11, 2021)
- Capital Clubhouse Named Finalist in DC Congresswoman Eleanor Holmes Norton’s Community Project Funding Initiative (April 28, 2021)
- In Bloomberg Law, Attorneys Analyze Potential Costs of Reshoring Pharmaceutical Manufacturing
(April 9, 2021)
- Event: Navigating Life Sciences M&A Under the Biden Administration | Drug Pricing & Antitrust Considerations (March 25, 2021)
- What the U.S. Federal Government Might Learn from States About Regulating Drug Pricing (March 24, 2021)
- Podcast: CMMI Program Delays and Suspensions—Recommended Next Steps (March 18, 2021)
- Law360 Profiles Tara Fisher on Guiding Novavax in Pursuit of COVID-19 Vaccine (March 11, 2021)
- In Law360, Health Care Attorneys Analyze Information Blocking Rule Opportunities for Clinical Research (March 9, 2021)
- Event: Outlook 2021 – Washington, D.C. Updates and Insights on Life Sciences and Health Care (February 25, 2021)
- In Law360, Margaux Hall Examines Drug Commercialization and Market Access Strategies in Light of Drug Pricing Regulatory Uncertainty Under the Biden Administration
(February 16, 2021)
- 2022 Medicare Advantage and Part D Final Rule Includes Update to Star Ratings System and Implementing Coverage and Transparency Measures (February 5, 2021)
-
Medicare Expands Coverage of “Breakthrough” Medical Devices and Codifies “Reasonable and Necessary” Standard
(January 21, 2021)
- Health Care Co-Chairs Address Key Issues Facing Health Payers in 2021
(January 8, 2021)
- In Law360, Tom Bulleit Analyzes 2021 Health Policies Under the Biden Administration (January 5, 2021)
- In Law360, Attorneys Evaluate 2021 IPO Market (January 5, 2021)
- The 2020 Election and Health Care (December 15, 2020)
- In Bloomberg Law, Tom Bulleit Discusses New “Stark” and Anti-Kickback Rules for Value-Based Arrangements (November 25, 2020)
- In Law360, Health Care Attorneys Examine State Drug Pricing Reforms (November 25, 2020)
Cookie Settings
